418 related articles for article (PubMed ID: 27807822)
21. Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats.
Pehrson AL; Hillhouse TM; Haddjeri N; Rovera R; Porter JH; Mørk A; Smagin G; Song D; Budac D; Cajina M; Sanchez C
J Pharmacol Exp Ther; 2016 Sep; 358(3):472-82. PubMed ID: 27402279
[TBL] [Abstract][Full Text] [Related]
22. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
Baune BT; Brignone M; Larsen KG
Int J Neuropsychopharmacol; 2018 Feb; 21(2):97-107. PubMed ID: 29053849
[TBL] [Abstract][Full Text] [Related]
23. What role for ▼vortioxetine?
Drug Ther Bull; 2016 Mar; 54(3):30-3. PubMed ID: 26966120
[TBL] [Abstract][Full Text] [Related]
24. Vortioxetine: first global approval.
Gibb A; Deeks ED
Drugs; 2014 Jan; 74(1):135-45. PubMed ID: 24311349
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
26. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huang IC; Chang TS; Chen C; Sung JY
Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
[TBL] [Abstract][Full Text] [Related]
27. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
30. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
32. [Full functional recovery in depression treatment. Clinical cases treated with vortioxetina].
Russo F
Riv Psichiatr; 2017; 52(3):129-134. PubMed ID: 28692076
[TBL] [Abstract][Full Text] [Related]
33. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
McIntyre RS; Lee Y
Curr Opin Psychiatry; 2016 Jan; 29(1):48-55. PubMed ID: 26575300
[TBL] [Abstract][Full Text] [Related]
34. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.
De Diego-Adeliño J; Crespo JM; Mora F; Neyra A; Iborra P; Gutiérrez-Rojas L; Salonia SF
Expert Opin Drug Saf; 2022 May; 21(5):673-690. PubMed ID: 34964415
[TBL] [Abstract][Full Text] [Related]
35. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
36. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
37. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
38. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
Adell A
IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
[TBL] [Abstract][Full Text] [Related]
39. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]